JP2020002154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020002154A5 JP2020002154A5 JP2019152602A JP2019152602A JP2020002154A5 JP 2020002154 A5 JP2020002154 A5 JP 2020002154A5 JP 2019152602 A JP2019152602 A JP 2019152602A JP 2019152602 A JP2019152602 A JP 2019152602A JP 2020002154 A5 JP2020002154 A5 JP 2020002154A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- disease
- treating
- purified peptide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 206010044696 Tropical spastic paresis Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000002537 cosmetic Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 4
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 208000005141 Otitis Diseases 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 208000019258 ear infection Diseases 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000023504 respiratory system disease Diseases 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 3
- 206010042496 Sunburn Diseases 0.000 claims 3
- 206010000496 acne Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000024963 hair loss Diseases 0.000 claims 3
- 230000003676 hair loss Effects 0.000 claims 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003499 exocrine gland Anatomy 0.000 claims 2
- 229940027941 immunoglobulin g Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000012264 purified product Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000335A JP2024029182A (ja) | 2011-01-18 | 2024-01-04 | γｃサイトカイン活性を調節するための組成物および方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161433890P | 2011-01-18 | 2011-01-18 | |
| US61/433,890 | 2011-01-18 | ||
| US201161527049P | 2011-08-24 | 2011-08-24 | |
| US61/527,049 | 2011-08-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017090501A Division JP6820230B2 (ja) | 2011-01-18 | 2017-04-28 | γｃサイトカイン活性を調節するための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000335A Division JP2024029182A (ja) | 2011-01-18 | 2024-01-04 | γｃサイトカイン活性を調節するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020002154A JP2020002154A (ja) | 2020-01-09 |
| JP2020002154A5 true JP2020002154A5 (enExample) | 2020-02-20 |
Family
ID=46516044
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550541A Active JP6395379B2 (ja) | 2011-01-18 | 2012-01-17 | γｃサイトカイン活性を調節するための組成物および方法 |
| JP2017090501A Expired - Fee Related JP6820230B2 (ja) | 2011-01-18 | 2017-04-28 | γｃサイトカイン活性を調節するための組成物および方法 |
| JP2019152602A Pending JP2020002154A (ja) | 2011-01-18 | 2019-08-23 | γｃサイトカイン活性を調節するための組成物および方法 |
| JP2024000335A Pending JP2024029182A (ja) | 2011-01-18 | 2024-01-04 | γｃサイトカイン活性を調節するための組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550541A Active JP6395379B2 (ja) | 2011-01-18 | 2012-01-17 | γｃサイトカイン活性を調節するための組成物および方法 |
| JP2017090501A Expired - Fee Related JP6820230B2 (ja) | 2011-01-18 | 2017-04-28 | γｃサイトカイン活性を調節するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000335A Pending JP2024029182A (ja) | 2011-01-18 | 2024-01-04 | γｃサイトカイン活性を調節するための組成物および方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US9133244B2 (enExample) |
| EP (3) | EP4461742A3 (enExample) |
| JP (4) | JP6395379B2 (enExample) |
| CN (2) | CN103501805B (enExample) |
| AU (3) | AU2012207456C1 (enExample) |
| BR (1) | BR112013018046B1 (enExample) |
| CA (1) | CA2824515C (enExample) |
| CY (1) | CY1122846T1 (enExample) |
| DK (2) | DK2665486T3 (enExample) |
| ES (2) | ES2989085T3 (enExample) |
| FI (1) | FI3636274T3 (enExample) |
| HR (1) | HRP20200470T1 (enExample) |
| LT (1) | LT2665486T (enExample) |
| PL (2) | PL3636274T3 (enExample) |
| PT (2) | PT2665486T (enExample) |
| RS (1) | RS60050B1 (enExample) |
| SI (1) | SI2665486T1 (enExample) |
| SM (1) | SMT202000142T1 (enExample) |
| WO (1) | WO2012099886A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015089217A2 (en) * | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| SI2665486T1 (sl) | 2011-01-18 | 2020-07-31 | Bioniz, Llc | Sestavki za moduliranje aktivnosti gama-C-citokina |
| CN104789527B (zh) * | 2015-05-15 | 2018-05-29 | 江苏杰晟生物科技有限公司 | 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品 |
| WO2017062685A1 (en) * | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| WO2017190684A1 (zh) * | 2016-05-06 | 2017-11-09 | 王牧林 | 白细胞介素组合及其用途 |
| US20210324029A1 (en) * | 2017-04-07 | 2021-10-21 | Bioniz, Llc | Stable modulators of gamma-c-cytokine activity |
| SG11202100561QA (en) * | 2018-07-19 | 2021-02-25 | Univ Tokyo | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CA3108865A1 (en) | 2018-08-06 | 2020-02-13 | Medikine, Inc. | Il-2 receptor binding compounds |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| WO2020227019A1 (en) * | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| KR102265435B1 (ko) * | 2019-08-20 | 2021-06-15 | 주식회사 케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
| AU2020378282B2 (en) | 2019-11-05 | 2023-05-18 | Medikine, Inc. | Dual IL-2R and IL-7R binding compounds |
| JP7427286B2 (ja) | 2019-11-05 | 2024-02-05 | メディカイン、インコーポレイテッド | ＩＬ－２ＲβγＣ結合化合物 |
| KR20220139918A (ko) | 2020-02-03 | 2022-10-17 | 메디카인 인코포레이티드 | IL-7Rαγc 결합 화합물 |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| CN115667523A (zh) | 2020-04-10 | 2023-01-31 | 西托姆克斯治疗公司 | 可活化细胞因子构建体和相关组合物以及方法 |
| CA3186973A1 (en) * | 2020-06-24 | 2021-12-30 | Bioniz, Llc | Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders |
| WO2022054565A1 (ja) | 2020-09-08 | 2022-03-17 | デクソンファーマシューティカルズ株式会社 | サイトカインストーム抑制剤、サイトカインストーム抑制剤の使用方法およびスクリーニング方法 |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| JP6974892B1 (ja) | 2021-05-27 | 2021-12-01 | デクソンファーマシューティカルズ株式会社 | 癌悪液質の改善剤および癌悪液質の改善方法 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5700913A (en) | 1982-12-15 | 1997-12-23 | Ajinomoto Co., Inc. | Unglycosylated human interleukin-2 polypeptides |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| IL80678A (en) | 1985-11-19 | 1999-05-09 | Schering Biotech Corp | Human interleukin-4 |
| US6028186A (en) | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US6037149A (en) | 1995-08-24 | 2000-03-14 | Magainin Pharmaceuticals Inc. | DNA encoding human asthma associated factor 1 |
| IL130238A0 (en) | 1999-06-01 | 2000-06-01 | Peptor Ltd | Conformationally constrained backbone cyclized interleukin-6 antagonists |
| AU2937597A (en) | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US6127387A (en) | 1996-12-10 | 2000-10-03 | Thomas Jefferson University | Use of CD4-binding small molecules to inhibit immune responses |
| EP1012184B1 (en) * | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US6861227B2 (en) | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| EP0972780A1 (en) * | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| JP2003533488A (ja) | 2000-05-12 | 2003-11-11 | ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド | 免疫抑制を達成するための組成物および方法 |
| CN1317301C (zh) | 2000-09-14 | 2007-05-23 | 贝斯以色列护理医疗中心有限公司 | Il－2－和il－15－介导的t细胞应答的调节 |
| MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
| US20040126900A1 (en) | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
| WO2003004098A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| US7825089B2 (en) | 2001-10-24 | 2010-11-02 | National Jewish Health | Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto |
| DE60233888D1 (de) | 2001-11-05 | 2009-11-12 | Zymogenetics Inc | Il-21-antagonisten |
| JP4511349B2 (ja) | 2002-01-18 | 2010-07-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー |
| AU2003226141A1 (en) | 2002-03-27 | 2003-10-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for treating cancer in humans |
| AU2003230834A1 (en) * | 2002-04-09 | 2003-10-27 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| CA2480777A1 (en) | 2002-05-01 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat hiv infection and aids |
| PT1531850E (pt) | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| JP2005535636A (ja) | 2002-06-28 | 2005-11-24 | アメリカ合衆国 | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 |
| AU2003251633A1 (en) | 2002-07-01 | 2004-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Il-21 as a regulator of immunoglobin production |
| KR20050037552A (ko) | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| US20060236411A1 (en) * | 2002-10-14 | 2006-10-19 | Ingeborg Dreher | Antagonists il-15 |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| MXPA05010035A (es) | 2003-03-21 | 2005-11-17 | Wyeth Corp | Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21. |
| DE602004028007D1 (de) | 2003-05-14 | 2010-08-19 | Bayer Pharmaceuticals Corp | Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren |
| CA2529520A1 (en) | 2003-06-19 | 2004-12-29 | Centocor, Inc. | Interleukin-21 analogs |
| DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7785580B2 (en) | 2003-08-29 | 2010-08-31 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| US7276478B2 (en) | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| WO2005067956A2 (en) | 2004-01-15 | 2005-07-28 | Novo Nordisk A/S | Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection |
| PL1751175T3 (pl) | 2004-05-05 | 2013-03-29 | Valorisation Recherche Soc En Commandite | Antagoniści receptora IL-1, kompozycje i sposoby leczenia |
| BRPI0510996A (pt) | 2004-05-19 | 2007-12-04 | Wyeth Corp | métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico |
| US20060039902A1 (en) | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| CU23472A1 (es) | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
| WO2006105538A2 (en) | 2005-03-31 | 2006-10-05 | Centocor, Inc. | Methods and compositions for treating il-21 related pathologies |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| ATE497975T1 (de) | 2005-04-18 | 2011-02-15 | Novo Nordisk As | Il-21-varianten |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1940734A2 (en) * | 2005-08-10 | 2008-07-09 | Northwestern University | Composite particles |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| JP5322653B2 (ja) | 2005-11-28 | 2013-10-23 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１アンタゴニスト |
| US7632814B2 (en) | 2006-09-07 | 2009-12-15 | University Of South Florida | HYD1 peptides as anti-cancer agents |
| EP2091968A2 (en) | 2006-10-26 | 2009-08-26 | Novo Nordisk A/S | Il-21 variants |
| AU2007336184A1 (en) | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the IL-21 receptor |
| US7910123B2 (en) | 2007-09-05 | 2011-03-22 | Warsaw Orthopedic | Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent |
| WO2009100035A2 (en) | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| EP2254998B1 (en) | 2008-02-28 | 2015-12-23 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
| WO2009132821A1 (en) | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| US20110091515A1 (en) * | 2008-06-12 | 2011-04-21 | Ramot At Tel-Aviv University Ltd. | Drug-eluting medical devices |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| US20100075329A1 (en) | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
| ES2620437T3 (es) | 2008-11-17 | 2017-06-28 | Københavns Universitet | Péptidos derivados de IL-4 para la modulación de la respuesta inflamatoria crónica y el tratamiento de enfermedades autoinmunes |
| CA2747790A1 (en) | 2009-01-05 | 2010-07-08 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| EP2406282A1 (en) | 2009-03-11 | 2012-01-18 | Novo Nordisk A/S | Interleukin-21 variants having antagonistic binding to the il-21 receptor |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| CA2783876C (en) | 2009-12-11 | 2018-04-03 | Proyecto De Biomedicina Cima, S.L. | New conjugates and compositions for immunotherapy and antitumoral treatment |
| CN102858367B (zh) * | 2010-02-26 | 2014-12-17 | 国立大学法人长崎大学 | 抗原或药物递送复合物 |
| US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| US8822642B2 (en) | 2010-06-09 | 2014-09-02 | Zymogenetics, Inc. | Dimeric fusion proteins and related compositions and methods |
| US9084761B2 (en) * | 2010-07-09 | 2015-07-21 | The Regents Of The University Of California | Use of interleukin-15 to treat cardiovascular diseases |
| EP2596023A4 (en) | 2010-07-20 | 2014-03-05 | Beth Israel Hospital | COMPOSITIONS AND METHODS FOR IL-6 AND IL-21 ANTAGONISTS |
| SI2665486T1 (sl) | 2011-01-18 | 2020-07-31 | Bioniz, Llc | Sestavki za moduliranje aktivnosti gama-C-citokina |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US9670672B2 (en) | 2014-12-03 | 2017-06-06 | Aleksandar Stevanov | Roof panel system |
| EP3350205A1 (en) | 2015-09-16 | 2018-07-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| US20170104927A1 (en) | 2015-10-07 | 2017-04-13 | Little Star Media, Inc. | Systems, methods and software programs for 360 degree video distribution platforms |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| CN110167957A (zh) | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| US20210324029A1 (en) | 2017-04-07 | 2021-10-21 | Bioniz, Llc | Stable modulators of gamma-c-cytokine activity |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
-
2012
- 2012-01-17 SI SI201231746T patent/SI2665486T1/sl unknown
- 2012-01-17 EP EP24188657.1A patent/EP4461742A3/en active Pending
- 2012-01-17 LT LTEP12736203.6T patent/LT2665486T/lt unknown
- 2012-01-17 HR HRP20200470TT patent/HRP20200470T1/hr unknown
- 2012-01-17 CN CN201280010348.8A patent/CN103501805B/zh active Active
- 2012-01-17 AU AU2012207456A patent/AU2012207456C1/en not_active Ceased
- 2012-01-17 SM SM20200142T patent/SMT202000142T1/it unknown
- 2012-01-17 BR BR112013018046-3A patent/BR112013018046B1/pt not_active IP Right Cessation
- 2012-01-17 DK DK12736203.6T patent/DK2665486T3/da active
- 2012-01-17 US US13/980,305 patent/US9133244B2/en active Active
- 2012-01-17 PL PL19206731.2T patent/PL3636274T3/pl unknown
- 2012-01-17 FI FIEP19206731.2T patent/FI3636274T3/fi active
- 2012-01-17 RS RS20200324A patent/RS60050B1/sr unknown
- 2012-01-17 CN CN201810863447.XA patent/CN109021069A/zh active Pending
- 2012-01-17 CA CA2824515A patent/CA2824515C/en active Active
- 2012-01-17 JP JP2013550541A patent/JP6395379B2/ja active Active
- 2012-01-17 PL PL12736203T patent/PL2665486T3/pl unknown
- 2012-01-17 ES ES19206731T patent/ES2989085T3/es active Active
- 2012-01-17 EP EP19206731.2A patent/EP3636274B1/en active Active
- 2012-01-17 PT PT127362036T patent/PT2665486T/pt unknown
- 2012-01-17 EP EP12736203.6A patent/EP2665486B1/en active Active
- 2012-01-17 WO PCT/US2012/021566 patent/WO2012099886A1/en not_active Ceased
- 2012-01-17 PT PT192067312T patent/PT3636274T/pt unknown
- 2012-01-17 DK DK19206731.2T patent/DK3636274T3/da active
- 2012-01-17 ES ES12736203T patent/ES2778053T3/es active Active
- 2012-08-17 US US13/589,017 patent/US8455449B2/en not_active Expired - Fee Related
-
2013
- 2013-04-23 US US13/868,725 patent/US9133243B2/en active Active
-
2015
- 2015-09-11 US US14/852,240 patent/US9675672B2/en not_active Expired - Fee Related
-
2016
- 2016-06-10 US US15/179,900 patent/US9951105B2/en active Active
-
2017
- 2017-01-25 AU AU2017200489A patent/AU2017200489B2/en not_active Ceased
- 2017-03-30 US US15/474,312 patent/US10227382B2/en active Active
- 2017-04-28 JP JP2017090501A patent/JP6820230B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-19 US US15/957,806 patent/US10808009B2/en active Active
-
2019
- 2019-03-06 US US16/294,733 patent/US11834519B2/en active Active
- 2019-04-11 AU AU2019202527A patent/AU2019202527B2/en not_active Ceased
- 2019-08-23 JP JP2019152602A patent/JP2020002154A/ja active Pending
-
2020
- 2020-03-20 CY CY20201100269T patent/CY1122846T1/el unknown
- 2020-09-04 US US17/012,724 patent/US11708392B2/en active Active
-
2023
- 2023-11-06 US US18/502,536 patent/US20240209025A1/en not_active Abandoned
-
2024
- 2024-01-04 JP JP2024000335A patent/JP2024029182A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020002154A5 (enExample) | ||
| JP2024029182A5 (enExample) | ||
| HRP20200470T1 (hr) | Pripravci za modulaciju aktivnosti gama-c-citokina | |
| Culley | Natural killer cells in infection and inflammation of the lung | |
| AU2020201174B2 (en) | Modulating gamma - c -cytokine activity | |
| JP2020513020A5 (enExample) | ||
| AU2018250210B2 (en) | Stable modulators of gamma-c-cytokine activity | |
| JP2012508698A5 (enExample) | ||
| HK40028404A (en) | Compositions for modulating gamma-c-cytokine activity | |
| HK1259668B (en) | Modulating gamma - c -cytokine activity |